TrialThe New England journal of medicine2019

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Tait D Shanafelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.